Combining Lactate Dehydrogenase and Fibrinogen: Potential Factors to Predict Therapeutic Efficacy and Prognosis of Patients with Small-Cell Lung Cancer

References

• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–1380. doi:10.1056/NEJMra080271418815398
   PubMed Web of Science ®Google Scholar
• Nilssen Y, Strand TE, Fjellbirkeland L, et al. Lung cancer survival in Norway, 1997–2011: from nihilism to optimism. Eur Respir J. 2016;47(1):275–287. doi:10.1183/13993003.00650-201526541525
   PubMed Web of Science ®Google Scholar
• Grivaux M, Duvert B, Ferrer-Lopez P, et al. One-year survival improvement in lung cancer in France. Results of the prospective real life studies KBP-2000-CPHG and KBP-2010-CPHG. Rev Pneumol Clin. 2016;72(3):163–170. doi:10.1016/j.pneumo.2016.02.00227113617
   PubMed Web of Science ®Google Scholar
• Li S, Yang Q, Wang H, et al. Prognostic significance of serum lactate dehydrogenase levels in Ewing’s sarcoma: a meta-analysis. Mol Clin Oncol. 2016;5(6):832–838. doi:10.3892/mco.2016.106628105365
   PubMedGoogle Scholar
• Ren X, Zhang Y, Lyu Y, et al. Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma. Cancer Biomark. 2019;26(2):139–150. doi:10.3233/CBM-19020131356196
   PubMed Web of Science ®Google Scholar
• Pelizzari G, Basile D, Zago S, et al. Lactate Dehydrogenase (LDH) response to first-line treatment predicts survival in metastatic breast cancer: first clues for a cost-effective and dynamic biomarker. Cancers (Basel). 2019;11(9):1243. doi:10.3390/cancers11091243
   PubMed Web of Science ®Google Scholar
• Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001;24(6):547–550. doi:10.1097/00000421-200112000-0000311801751
   PubMed Web of Science ®Google Scholar
• Hermes A, Waschki B, Reck M. Hyponatremia as prognostic factor in small cell lung cancer: a retrospective single institution analysis. Respir Med. 2012;106(6):900–904. doi:10.1016/j.rmed.2012.02.01022405607
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961–970. doi:10.3109/0284186X.2015.104302625984930
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo M, Fan J, et al. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark. 2016;16(3):415–423. doi:10.3233/CBM-16058027062698
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Go SI, Kim RB, Song HN, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Med Oncol. 2014;31(12):323. doi:10.1007/s12032-014-0323-y25417187
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res. 2019;8(3):214–226. doi:10.21037/tlcr.2019.06.1031367535
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.02428838390
   PubMed Web of Science ®Google Scholar
• Ozmen S, Timur O, Calik I, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Regul. 2017;51(3):131–136. doi:10.1515/enr-2017-001328858848
   PubMedGoogle Scholar
• Fan S, Guan Y, Zhao G, et al. Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma. Thorac Cancer. 2018;9(1):146–151. doi:10.1111/1759-7714.1255629131503
   PubMed Web of Science ®Google Scholar
• Zhu LR, Li J, Chen P, et al. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clin Transl Oncol. 2016;18(2):178–188. doi:10.1007/s12094-015-1350-726184726
   PubMed Web of Science ®Google Scholar
• Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer. 2013;109(5):1123–1129. doi:10.1038/bjc.2013.44323922109
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Ikeuchi S, Kitagawa Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22(12):2222–2227. doi:10.1111/j.1440-1746.2006.04736.x18031385
   PubMed Web of Science ®Google Scholar
• Monraats PS, Rana JS, Zwinderman AH, et al. -455G/A polymorphism and preprocedural plasma levels of Fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost. 2005;93(3):564–569. doi:10.1160/TH04-11-070815735811
   PubMed Web of Science ®Google Scholar
• Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894–1904. doi:10.1111/j.1538-7836.2005.01365.x16102057
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997;33(1):50–55. doi:10.1016/S0959-8049(96)00310-39071899
   PubMed Web of Science ®Google Scholar
• Lillicrap D. Introduction to a series of reviews on cancer-associated thrombotic disease. Blood. 2013;122(10):1687–1688. doi:10.1182/blood-2013-05-49908723798712
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302–3309. doi:10.1182/blood.V96.10.330211071621
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Potter JM, Kaplan LS, et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62(23):6966–6972.12460914
   PubMed Web of Science ®Google Scholar
• Oh JR, Seo JH, Chong A, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(6):925–935. doi:10.1007/s00259-011-2059-722270509
   PubMed Web of Science ®Google Scholar
• Kuo YW, Jerng JS, Shih JY, et al. The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma. J Thorac Oncol. 2011;6(2):378–383. doi:10.1097/JTO.0b013e3181fd410721173715
   PubMed Web of Science ®Google Scholar
• Harmsma M, Schutte B, Ramaekers FC. Serum markers in small cell lung cancer: opportunities for improvement. Biochim Biophys Acta. 2013;1836(2):255–272. doi:10.1016/j.bbcan.2013.06.00223796706
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89(5):877–885. doi:10.1038/sj.bjc.660120512942121
   PubMed Web of Science ®Google Scholar
• Liu D, Huang Y, Li L, et al. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer. 2017;17(1):882. doi:10.1186/s12885-017-3893-129268698
   PubMed Web of Science ®Google Scholar
• Hirose T, Okuda K, Yamaoka T, et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase± at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung Cancer. 2011;71(2):224–228. doi:10.1016/j.lungcan.2010.05.00420537424
   PubMed Web of Science ®Google Scholar
• Miura K, Hamanaka K, Koizumi T, et al. Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: comparative study of normal lung, emphysema, and pulmonary fibrosis. Lung Cancer. 2017;111:88–95. doi:10.1016/j.lungcan.2017.07.00328838406
   PubMed Web of Science ®Google Scholar